113305-94-5

Basic information

• Product Name: 2-AMINO-5-CYANOPYRAZINE
• Synonyms: IFLAB-BB F2108-0176;5-AMINOPYRAZINE-2-CARBONITRILE;2-AMINO-5-CYANOPYRAZINE;5-amino-5-cyanopyrazine;2-AMINO-5-CYANOPYRAZINE, 95+%;5-AMINO-2-CYANOPYRAZINE;Pyrazinecarbonitrile, 5-amino-;5-Aminopyrazine-2-Carbonitrile(WX609404)
• CAS NO: 113305-94-5
• Molecular Formula: C₅H₄N₄
• Molecular Weight: 120.11
• Product Categories: Boron, Nitrile, Thio,& TM-Cpds;Heterocycles;Piperazine series;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines;Building Blocks;Pyrazine
• Mol File: 113305-94-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 366.752 °C at 760 mmHg
• Flash Point: 175.605 °C
• Appearance: /
• Density: 1.346 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.727
• Storage Temp.: 2-8°C(protect from light)
• PKA: 0.98±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-5-CYANOPYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-CYANOPYRAZINE(113305-94-5)
• EPA Substance Registry System: 2-AMINO-5-CYANOPYRAZINE(113305-94-5)

Safety Data

• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 113305-94-5(Hazardous Substances Data)

Usage

General Description

2-AMINO-5-CYANOPYRAZINE, also known as 2-amino-5-cyanopyrazine, is a chemical compound with the molecular formula C5H4N4. It is a heterocyclic organic compound that consists of a pyrazine ring with an amino group at position 2 and a cyano group at position 5. This chemical has a variety of potential industrial applications, including potential use as a pharmaceutical intermediate. Additionally, it has been identified as a compound present in certain food products, including roasted coffee and bread crust. Its chemical structure and properties make it an important molecule for various areas of research and potential industrial use.

InChI:InChI=1/C8H6ClN3/c9-6-2-1-5-4-11-8(10)12-7(5)3-6/h1-4H,(H2,10,11,12)

Upstream product

• 59489-71-3 5-amino-2-bromopyrazine 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 
• 544-92-3 copper(I) cyanide 
• 557-21-1 zinc(II) cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 911223-11-5 2-{2-[3-(5-cyano-pyrazin-2-yl)-ureido]-4-methyl-phenoxymethyl}-morpholine-4-carboxylic acid tert-butyl ester 
• 710322-14-8 2(R)-(4-methanesulfonyl-phenyl)-3-cyclopentyl-5-bromo-pyrazin-2-yl-propionamide 
• 13924-94-2 5-amino-pyrazine-2-carboxylic acid methyl ester 
• 1276056-81-5 imidazo[1,2-a]pyrazine-6-carbonitrile 
• 1428417-71-3 (R)-3-chloro-α-(cyclopentylmethyl)-N-[2-[[[[[(9H-fluoren-9-yl)methoxy]carbonyl]oxy]-amino]iminomethyl]-5-pyrazinyl]-4-(methylsulfonyl)benzeneacetamide 
• 1428417-69-9 C₂₀H₂₄ClN₅O₄S 
• 1437718-52-9 (2-{2-chloro-4-[3-(5-cyano-pyrazin-2-yl)-ureido]-5-methoxy-phenoxy}-ethyl)-(2-morpholin-4-yl-ethyl)-carbamic acid tert-butyl ester 
• 1437870-64-8 N-(2-(2-chloro-4-[3-(5-cyano-pyrazin-2-yl)-ureido]-5-methoxy-phenyl)-ethyl)-2-morpholin-4-yl-acetamide 

Relevant articles and documents

Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors

A novel class of potent PI3Kδ inhibitors with >1000-fold selectivity against other class I PI3K isoforms is described. Optimization of the substituents on a triazole aminopyrazine scaffold, emerging from an in-house PI3Kα program, turned moderately selective PI3Kδ compounds into highly potent and selective PI3Kδ inhibitors. These efforts resulted in a series of aminopyrazines with PI3Kδ IC50???1?nM in the enzyme assay, some of the most selective PI3Kδ inhibitors published to date, with a cell potency in a JeKo-cell assay of 20–120?nM.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Substituted piperazines as metabotropic glutamate receptor antagonists

The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, Ar2, Hy, L, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.